Bicara CFO Sells Shares as Company Advances Phase 3 Dose Selection for Ficerafusp Alfa
Bicara Therapeutics CFO Ivan Hyep sold 1,882 shares on January 22, 2026, while exercising options for the same number of shares under a previously adopted Rule 10b5-1 trading plan. The company has selected a 1500 mg dose of ficerafusp alfa for its Phase 3 FORTIFI-HN01 study in first-line HPV-negative recurrent/metastatic head and neck squamous cell…